Should I buy or sell Armata Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARMP shares. View ARMP analyst ratings or view top-rated stocks .

What is Armata Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 12 month price targets for Armata Pharmaceuticals' stock. Their ARMP share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 239.8% from the stock's current price. View analysts price targets for ARMP or view top-rated stocks among Wall Street analysts .

Are investors shorting Armata Pharmaceuticals?

Armata Pharmaceuticals saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 99,700 shares, a decline of 25.4% from the October 15th total of 133,700 shares. Based on an average daily volume of 38,800 shares, the short-interest ratio is currently 2.6 days. Currently, 0.9% of the shares of the company are sold short. View Armata Pharmaceuticals' Short Interest .

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02. The business earned $1.23 million during the quarter, compared to analyst estimates of $0.90 million. Armata Pharmaceuticals had a negative trailing twelve-month return on equity of 280.95% and a negative net margin of 1,468.73%.

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV) , Vaxart (VXRT) , Amarin (AMRN) , CRISPR Therapeutics (CRSP) , Pfizer (PFE) , Micron Technology (MU) , Aduro Biotech (ADRO) , Occidental Petroleum (OXY) and Gilead Sciences (GILD) .

Who are Armata Pharmaceuticals' major shareholders?

Armata Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Armata Pharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:ARMP)

$2.06

+0.03 (+1.48%)

(As of 11/28/2023 ET)

Compare

Today's Range: $1.99
▼
$2.12
50-Day Range: N/A
52-Week Range: $0.83
▼
$5.26

Volume: 1,722 shs
Average Volume: 59,191 shs
Market Capitalization: $74.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Stock Analysis Analyst Forecasts Chart Earnings Headlines Ownership Short Interest

Armata Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 239.8% Upside
$7.00 Price Target
Short Interest: Healthy
0.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.71) to ($0.88) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Armata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Armata Pharmaceuticals has a forecasted upside of 239.8% from its current price of $2.06.
Amount of Analyst Coverage
Armata Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.90% of the float of Armata Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Armata Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in Armata Pharmaceuticals has recently decreased by 0.90%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Armata Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Armata Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARMP.

1.1

News and Social Media Coverage

News Sentiment
Armata Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Armata Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
3 people have searched for ARMP on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
85.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 3.28% of the stock of Armata Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Armata Pharmaceuticals are expected to grow in the coming year, from ($1.71) to ($0.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Armata Pharmaceuticals is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Armata Pharmaceuticals is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Armata Pharmaceuticals has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP)

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

ARMP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARMP Stock News Headlines

November 20, 2023 | americanbankingnews.com

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) to Post Q4 2023 Earnings of ($0.36) Per Share, HC Wainwright Forecasts

November 15, 2023 | markets.businessinsider.com

Robust Advancements and Strategic Planning: Key Drivers for Armata Pharmaceuticals’ Buy Rating

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

November 15, 2023 | finance.yahoo.com

Armata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Results and Corporate Updates

November 15, 2023 | finanznachrichten.de

Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

November 14, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

November 6, 2023 | money.usnews.com

Lexeo Therapeutics Inc.

October 30, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

October 19, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

October 4, 2023 | msn.com

Armata Pharmaceuticals (ARMP) Price Target Increased by 14.29% to 8.16

September 28, 2023 | markets.businessinsider.com

Armata Pharmaceuticals: Promising Clinical Trials and New Leadership Bolster Buy Recommendation

September 26, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

September 21, 2023 | finance.yahoo.com

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

August 22, 2023 | uk.news.yahoo.com

Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why

August 17, 2023 | finance.yahoo.com

Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?

August 15, 2023 | markets.businessinsider.com

Ladenburg Thalmann & Co. Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)

August 14, 2023 | finanznachrichten.de

Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

August 14, 2023 | seekingalpha.com

Armata Pharmaceuticals GAAP EPS of -$0.17, revenue of $0.98M

August 14, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

August 14, 2023 | finance.yahoo.com

ARMP - Armata Pharmaceuticals, Inc.

July 24, 2023 | benzinga.com

Dow Surges 150 Points; Domino's Pizza Earnings Top Expectations

July 11, 2023 | msn.com

Armata Pharmaceuticals gets $25M in financing and new executive chief

May 31, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 12, 2023 | msn.com

HC Wainwright & Co. Reiterates Armata Pharmaceuticals (ARMP) Buy Recommendation

May 12, 2023 | finanznachrichten.de

Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

May 11, 2023 | seekingalpha.com

Armata Pharmaceuticals GAAP EPS of -$0.40, revenue of $0.79M

See More Headlines

Receive ARMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:ARMP
CUSIP: N/A
CIK: N/A
Web: www.armatapharma.com
Phone: (310) 655-2928
Fax: 310-665-2963
Employees: 72
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +230.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,920,000.00
Net Margins: -1,468.73%
Pretax Margin: -1,468.71%
Return on Equity: -280.95%
Return on Assets: -43.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.67
Quick Ratio: 1.67

Sales & Book Value

Annual Sales: $5.51 million
Price / Sales: 13.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.00 per share
Price / Book: 2.12

Miscellaneous

Outstanding Shares: 36,150,000
Free Float: 5,241,000
Market Cap: $76.64 million
Optionable: Not Optionable
Beta: 0.99

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Mina Pastagia M.D. (Age 48)
MS, Chief Medical Officer
Comp: $537.6k
Dr. Deborah L. Birx M.D. (Age 66)
CEO & Director
Dr. Wenyuan Shi Ph.D.
Co-Founder & Founding Scientist
Mr. Richard Rychlik (Age 67)
VP, Corporate Controller & Principal Financial Officer
Mr. Bryan Kadotani
Vice President of Program Management & Operations
Dr. Pierre Kyme Ph.D.
Vice President of Business & Corporate Development

Key Competitors

View All Competitors

ARMP Stock Analysis - Frequently Asked Questions

Should I buy or sell Armata Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARMP shares.
View ARMP analyst ratings or view top-rated stocks.
What is Armata Pharmaceuticals' stock price target for 2024?: 1 equities research analysts have issued 12 month price targets for Armata Pharmaceuticals' stock. Their ARMP share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 239.8% from the stock's current price.
View analysts price targets for ARMP or view top-rated stocks among Wall Street analysts.
Are investors shorting Armata Pharmaceuticals?: Armata Pharmaceuticals saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 99,700 shares, a decline of 25.4% from the October 15th total of 133,700 shares. Based on an average daily volume of 38,800 shares, the short-interest ratio is currently 2.6 days. Currently, 0.9% of the shares of the company are sold short.
View Armata Pharmaceuticals' Short Interest.
How were Armata Pharmaceuticals' earnings last quarter?: Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02. The business earned $1.23 million during the quarter, compared to analyst estimates of $0.90 million. Armata Pharmaceuticals had a negative trailing twelve-month return on equity of 280.95% and a negative net margin of 1,468.73%.

What other stocks do shareholders of Armata Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Micron Technology (MU), Aduro Biotech (ADRO), Occidental Petroleum (OXY) and Gilead Sciences (GILD).
Who are Armata Pharmaceuticals' major shareholders?: Armata Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Armata Pharmaceuticals?: Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ARMP) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial